Casdin Capital, an investment firm, led a $83m Series B funding round in Celsius Therapeutics, a biotechnology company, with participation from Alexandria Venture Investments, GV, Heritage Provider Network, Third Rock Ventures, Amgen Ventures, Amplitude Ventures, Catalio Capital, Fast Track Initiative and Section 32. “We have successfully scaled our SCOPE (Single Cell Observations for Precision Effect) platform to allow us to discover therapeutic targets of high interest in IBD and solid tumors. In addition, our approach allows us to identify patient stratification hypotheses based on cell types and cell signatures, expanding the reach of precision medicine into new territory. We have now performed single cell RNA sequencing of over 1000 clinical tissue samples using this platform technology and our dataset continues to grow rapidly. We are excited to be fulfilling the vision of Celsius as we advance a potential first-in-class TREM1 antibody program for IBD and look to design smarter clinical studies based on biologic insights from our proprietary platform,” Tariq Kassum, Celsius CEO.